{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T14:42:41Z","timestamp":1774708961091,"version":"3.50.1"},"reference-count":32,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,8,8]]},"DOI":"10.1253\/circrep.cr-24-0185","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T18:07:21Z","timestamp":1751047641000},"page":"627-638","source":"Crossref","is-referenced-by-count":1,"title":["Prefectural Survey on Anthracycline-Related Cardiomyopathy at the Start of the Basic Plan to Promote Cancer Control Programs - Phase 4"],"prefix":"10.1253","volume":"7","author":[{"given":"Yuji","family":"Okura","sequence":"first","affiliation":[{"name":"Department of Onco-Cardiology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohito","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Health and Nutrition, Faculty of Human Life Studies, University of Niigata Prefecture"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kashimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Department of Hematology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Ikarashi","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuko","family":"Kanbayashi","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiko","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Niigata City General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tsuchida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Niigata City General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Hematology\/Oncology, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology, Faculty of Pharmacy, Niigata University of Pharmacy and Medical and Life Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Niigata Cancer Center Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the OCAN 2020 Collaborators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Watanabe M, Fujiki S, Okura Y, Toshikawa C, Ikarashi M, Kanbayashi C, et al. Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: Thirty-one-year trends in a Japanese Community. <i>Breast Cancer<\/i> 2024; 31: 1080\u20131091.","DOI":"10.1007\/s12282-024-01623-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kenigsberg B, Wellstein A, Barac A. Left Ventricular dysfunction in cancer treatment: Is it relevant? <i>JACC Heart Fail<\/i> 2018; 6: 87\u201395.","DOI":"10.1016\/j.jchf.2017.08.024"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. <i>Ann Oncol<\/i> 2002; 13: 699\u2013709.","DOI":"10.1093\/annonc\/mdf132"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. <i>Nat Rev Cardiol<\/i> 2015; 12: 547\u2013558.","DOI":"10.1038\/nrcardio.2015.65"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Padegimas A, Clasen S, Ky B. Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. <i>Trends Cardiovasc Med<\/i> 2020; 30: 22\u201328.","DOI":"10.1016\/j.tcm.2019.01.006"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Popat S, Smith IE. Therapy insight: Anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. <i>Nat Clin Pract Oncol<\/i> 2008; 5: 324\u2013335.","DOI":"10.1038\/ncponc1090"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Inoue K, Machino-Ohtsuka T, Nakazawa Y, Iida N, Sasamura R, Bando H, et al. Early detection and prediction of anthracycline-induced cardiotoxicity: A prospective cohort study. <i>Circ J<\/i> 2024; 88: 751\u2013759.","DOI":"10.1253\/circj.CJ-24-0065"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J<\/i> 2022; 43: 4229\u20134361.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"9","unstructured":"9. Japanese National Plan for Promotion of Measures Against Cerebrovascular and Cardiovascular Disease: Phase 2. Cabinet decision report from the Ministry of Health, Labor and Welfare on March 28, 2023 [in Japanese]. https:\/\/www.mhlw.go.jp\/content\/10905000\/001077712.pdf (accessed June 16, 2025)."},{"key":"10","unstructured":"10. Basic Plan to Promote Cancer Control Programs: Phase 4. Cabinet decision report from the Ministry of Health, Labor and Welfare on March 28, 2023 [in Japanese]. https:\/\/www.mhlw.go.jp\/content\/10901000\/001077913.pdf (accessed June 16, 2025)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Okura Y, Miura S, Tanabe N, Ozaki K, Kashimura T, Kikuchi A, et al. A prefectural survey on immune checkpoint inhibitor-associated myocarditis at the start of the basic plan to promote cancer control programs - Phase 4. <i>Circ Rep<\/i> 2025; 7: 176\u2013182.","DOI":"10.1253\/circrep.CR-24-0171"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. <i>J Clin Epidemiol<\/i> 2004; 57: 1096\u20131103.","DOI":"10.1016\/j.jclinepi.2004.04.005"},{"key":"13","unstructured":"13. Cancer Registration Reporting Medical Institutions (2020) in Cancer Registry of Niigata Prefecture, standard tally for 2020. 2024; 83\u201384 (in Japanese). https:\/\/www.kenko-niigata.com\/material\/files\/group\/4\/R2_niigata_gantouroku.pdf (accessed February 11, 2025)."},{"key":"14","unstructured":"14. Japanese Society of Medical Oncology, Japanese Onco-Cardiology Society, editors. Onco-cardiology guideline, 1st ed. Tokyo: Nankodo; 2023 [in Japanese]."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). <i>Circulation<\/i> 2001; 104: 2996\u20133007.","DOI":"10.1161\/hc4901.102568"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2016; 37: 2768\u20132801.","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol<\/i> 2017; 35: 893\u2013911.","DOI":"10.1200\/JCO.2016.70.5400"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Ann Oncol<\/i> 2020; 31: 171\u2013190.","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Henry ML, Niu J, Zhang N, Giordano SH, Chavez-MacGregor M. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients. <i>JACC Cardiovasc Imaging<\/i> 2018; 11: 1084\u20131093.","DOI":"10.1016\/j.jcmg.2018.06.005"},{"key":"20","unstructured":"20. Oka T. Development of onco-cardiology in Japan. <i>Nihon Rinsho<\/i> 2024; 82: 19\u201325 [in Japanese]."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Okura Y, Ozaki K, Tanaka H, Takenouchi T, Sato N, Minamino T. The impending epidemic of cardiovascular diseases in patients with cancer in Japan. <i>Circ J<\/i> 2019; 83: 2191\u20132202.","DOI":"10.1253\/circj.CJ-19-0426"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Bloom MW, Vo JB, Rodgers JE, Ferrari AM, Nohria A, Deswal A, et al. Cardio-oncology and heart failure: A scientific statement from the Heart Failure Society of America. <i>J Card Fail<\/i> 2025; 31: 415\u2013455.","DOI":"10.1016\/j.cardfail.2024.08.045"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Raisi-Estabragh Z, Murphy AC, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds KL, et al. Cardiovascular considerations before cancer therapy: Gaps in evidence and <i>JACC: CardioOncology<\/i> Expert Panel Recommendations. <i>JACC CardioOncol<\/i> 2024; 6: 631\u2013654.","DOI":"10.1016\/j.jaccao.2024.07.017"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Leong DP, Waliany S, Abdel-Qadir H, Atkins KM, Neilan TG, Lang NN, et al. Cardiovascular considerations during cancer therapy: Gaps in evidence and <i>JACC: CardioOncology<\/i> Expert Panel Recommendations. <i>JACC CardioOncol<\/i> 2024; 6: 815\u2013834.","DOI":"10.1016\/j.jaccao.2024.06.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Blaes A, Nohria A, Armenian S, Bergom C, Thavendiranathan P, Barac A, Sanchez-Petitto G, et al. Cardiovascular considerations after cancer therapy: Gaps in evidence and <i>JACC: CardioOncology<\/i> Expert Panel Recommendations. <i>JACC CardioOncol<\/i> 2025; 7: 1\u201319.","DOI":"10.1016\/j.jaccao.2024.06.006"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Henriksen PA, Hall P, MacPherson IR, Joshi SS, Singh T, Maclean M, et al. Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: The Cardiac CARE Trial. <i>Circulation<\/i> 2023; 148: 1680\u20131690.","DOI":"10.1161\/CIRCULATIONAHA.124.069375"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Austin D, Maier RH, Akhter N, Sayari M, Ogundimu E, Maddox JM, et al. Preventing cardiac damage in patients treated for breast cancer and lymphoma: The PROACT Clinical Trial. <i>JACC CardioOncol<\/i> 2024; 6: 684\u2013696.","DOI":"10.1016\/j.jaccao.2024.07.010"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kitaoka H, Tsutsui H, Kubo T, Ide T, Chikamori T, Fukuda K, et al. JCS\/JHFS 2018 guideline on the diagnosis and treatment of cardiomyopathies. <i>Circ J<\/i> 2021; 85: 1590\u20131689.","DOI":"10.1253\/circj.CJ-20-0910"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Arafa A, Kokubo Y, Kashima R, Teramoto M, Sakai Y, Nosaka S, et al. The Lifelong Health Support 10: A Japanese prescription for a long and healthy life. <i>Environ Health Prev Med<\/i> 2022; 27: 23.","DOI":"10.1265\/ehpm.22-00085"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Lau ES, Paniagua SM, Liu E, Jovani M, Li SX, Takvorian K, et al. Cardiovascular risk factors are associated with future cancer. <i>JACC CardioOncol<\/i> 2021; 3: 48\u201358.","DOI":"10.1016\/j.jaccao.2020.12.003"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Eyre H, Kahn R, Robertson RM, Clark NG, Doyle C, Hong Y, et al.; American Cancer Society; American Diabetes Association; American Heart Association. Preventing cancer, cardiovascular disease, and diabetes: A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. <i>Circulation<\/i> 2004; 109: 3244\u20133255.","DOI":"10.1161\/01.CIR.0000133321.00456.00"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/8\/7_CR-24-0185\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:37:40Z","timestamp":1754710660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/8\/7_CR-24-0185\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-24-0185","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"article-number":"CR-24-0185"}}